The Association supports patients and their families, provides access to reliable information, promotes disease awareness, and advocates for the highest standards of care and optimal treatment.
Who We Are
The Israel Amyloidosis Association was founded by patients for patients. We support individuals and families affected by AL Amyloidosis, hereditary ATTR (hATTR), and wild-type ATTR (ATTRwt). Our mission is to provide trusted information, emotional support, practical guidance and, whenever possible, financial assistance, while promoting research and improving patient care.
Our Activities
- Active WhatsApp and Facebook patient communities.
- Peer Mentoring Program for newly diagnosed patients.
- Educational lectures, conferences and patient workshops.
- Financial support for amyloid typing tests performed abroad when clinically required.
- Advocacy with healthcare providers, researchers and policy makers to improve access to diagnosis and treatment.
Advocacy for Innovation
The Association has played a significant role in advancing CAR-T therapy for AL Amyloidosis in Israel. Through continuous advocacy, collaboration with leading physicians and modest support for clinical development, our activities contributed to making Israel the only country in the world where CAR-T therapy is available for eligible patients with AL Amyloidosis.